SEC 13F Intelligence

Managers / Q4 2021 · view latest →

Lion Point Capital, LP

CIK 0001643354 · 375 PARK AVE, SUITE 2609, NEW YORK, NY, 10152 · 212-356-6200

Reported Value
$373M
Q4 2021
Positions
33
Filings on Record
31
2019–present window
Filed
Feb 14, 2022
original filing

Summary

Lion Point Capital, LP reported $373M in U.S.-listed holdings across 33 positions for Q4 2021.

Its largest position, Marinus Pharmaceuticals, represents 11.6% of the portfolio.

Compared with Q3 2021, the fund opened 10 new positions and exited 14.

Portfolio Metrics

Turnover
+30.5%
vs prior filed quarter
Top-10 Concentration
+65.4%
share of reported value
Largest Position
+11.6%
Marinus Pharmaceuticals
New / Exited
10 / 14
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $636MQ4 ’18Q1 ’19: $1.1BQ2 ’19: $1.0BQ3 ’19: $897MQ4 ’19: $1.1BQ4 ’19Q1 ’20: $379MQ2 ’20: $412MQ3 ’20: $456MQ4 ’20: $519MQ4 ’20Q1 ’21: $550MQ2 ’21: $579MQ3 ’21: $533MQ4 ’21: $373MQ4 ’21Q1 ’22: $431MQ2 ’22: $878MQ3 ’22: $454MQ4 ’22: $703MQ4 ’22Q1 ’23: $243MQ2 ’23: $221MQ3 ’23: $224MQ4 ’23: $200MQ4 ’23Q1 ’24: $179MQ2 ’24: $55MQ3 ’24: $45MQ4 ’24: $19MQ4 ’24Q1 ’25: $16MQ2 ’25: $15MQ3 ’25: $18MQ4 ’25: $19MQ4 ’25Q1 ’26: $17Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 87.2%Other: 8.9%ETP: 3.2%US DOMESTIC: 0.7%
  • Common Stock · 87.2% · $325M
  • Other · 8.9% · $33M
  • ETP · 3.2% · $12M
  • US DOMESTIC · 0.7% · $3M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CTXSEURCITRIX SYS INCNEW+279.8K279.8K+$26M$26M
KDKYNDRYL HLDGS INCNEW+1.00M1.00M+$18M$18M
CIVICIVITAS RESOURCES INCNEW+320.4K320.4K+$16M$16M
ENPHYS ACQUISITION CORPNEW+1.23M1.23M+$12M$12M
SPDR SER TRNEW+125.0K125.0K+$12M$12M
CHRDOASIS PETROLEUM INCNEW+50.0K50.0K+$6M$6M
ERFGBPENERPLUS CORPNEW+575.0K575.0K+$6M$6M
VASCULAR BIOGENICS LTDNEW+2.59M2.59M+$5M$5M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2021

28 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MARINUS PHARMACEUTICALS INCCOM NEW11.56%$43M3.63M
2ARCONIC CORPORATIONCOM10.73%$40M1.21M
3SWCHFSIERRA WIRELESS INChistory →COM10.13%$38M2.14M
4CPE*CALLON PETE CO DELhistory →COM6.68%$25M527.5K
5TGTXTG THERAPEUTICS INChistory →COM5.91%$22M1.16M
61T7TRICIDA INChistory →COM4.68%$17M1.83M
7CIVICIVITAS RESOURCES INChistory →COM NEW4.21%$16M320.4K
80LSBURGERFI INTERNATIONAL INChistory →COM4.17%$16M2.75M
9DRRXEURDURECT CORPhistory →COM4.09%$15M15.49M
10ENPHYS ACQUISITION CORPUNIT 99/99/99993.26%$12M1.23M
11OPHTEURIVERIC BIO INChistory →COM3.17%$12M706.2K
12RENEW ENERGY GLOBAL PLCCL A SHS2.09%$8M1.00M
13CHRDOASIS PETROLEUM INChistory →COM NEW1.69%$6M50.0K
14ERFGBPENERPLUS CORPhistory →COM1.63%$6M575.0K
15VASCULAR BIOGENICS LTDCOM1.37%$5M2.59M
16MCRB1EURSERES THERAPEUTICS INChistory →COM1.08%$4M481.8K
17BATLBATTALION OIL CORPORATIONCOM0.93%$3M352.9K
18CTIC1USDCTI BIOPHARMA CORPCOM0.81%$3M1.22M
19LIBERTY GLOBAL PLCSHS CL A0.74%$3M100.0K
20IQIYI INCNOTE 4.000%12/10.74%$3M4.00M
21INNOVIZ TECHNOLOGIES LTDSHS0.68%$3M400.0K
22AGLEUSDAEGLEA BIOTHERAPEUTICS INCCOM0.38%$1M300.0K
23KINIKSA PHARMACEUTICALS LTDCOM CL A0.17%$647,00055.0K
24ORIGIN MATERIALS INCCOM0.17%$645,000100.0K
25LUMOS PHARMA INCCOM0.09%$354,00051.2K
26SDIGSTRONGHOLD DIGITAL MINING INCLASS A COM0.07%$257,00020.0K
27AAALCOA CORPCOM0.02%$59,0001.0K
28SCOR1EURCOMSCORE INCCOM0.00%$3,0001.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$17M35May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$19M39Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$18M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$15M19Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$16M21May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$19M19Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$45M25Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$55M27Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$179M32May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$200M30Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$224M31Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$221M30Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$243M31May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$703M32Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$454M41Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$878M40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$431M35May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$373M33Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$533M38Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$579M34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$550M30May 19, 2021RESTATEMENTchanges · EDGAR ↗
Q4 2020$519M24Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$456M24Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$412M24Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$379M25May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.1B26Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$897M26Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.0B24Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.1B24May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$636M35Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.